Adapting antibodies for clinical use.
- 28 November 1992
- Vol. 305 (6865) , 1348-1352
- https://doi.org/10.1136/bmj.305.6865.1348
Abstract
Techniques for antibody engineering are now overcoming the problems that have prevented monoclonal antibodies being used routinely in clinical practice. With chemical and genetic manipulation antibodies can be linked to bacterial toxins, enzymes, radionuclides, or cytotoxic drugs, allowing targeting of treatment. Antigen binding sites from antibodies raised in mice can be jointed with human IgG to reduce immunogenicity. In vitro gene amplification and genetic engineering of bacteriophage have produced large antibody gene libraries and facilitated large scale production of human monoclonal antibodies with high specificity. The trickle of monoclonal antibodies into clinical practice may soon become a flood.Keywords
This publication has 24 references indexed in Scilit:
- Discovery of antibodies.BMJ, 1992
- Selection of phage antibodies by binding affinityJournal of Molecular Biology, 1992
- By–Passing Immunization: Building High Affinity Human Antibodies by Chain ShufflingNature Biotechnology, 1992
- Therapeutic advantage of high-affinity anticarcinoma radioimmunoconjugates.1992
- In-cell PCR from mRNA: amplifying and linking the rearranged immunoglobulin heavy and light chain V-genes within single cellsNucleic Acids Research, 1992
- Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity.Proceedings of the National Academy of Sciences, 1989
- Cloning immunoglobulin variable domains for expression by the polymerase chain reaction.Proceedings of the National Academy of Sciences, 1989
- REMISSION INDUCTION IN NON-HODGKIN LYMPHOMA WITH RESHAPED HUMAN MONOCLONAL ANTIBODY CAMPATH-1HThe Lancet, 1988
- Assembly of a Functional Immunoglobulin F v Fragment in Escherichia coliScience, 1988
- A hapten-specific chimaeric IgE antibody with human physiological effector functionNature, 1985